KCNE3 Gene Brugada Syndrome Type 6 NGS Genetic DNA Test
Understanding Brugada Syndrome Type 6 and KCNE3 Genetic Testing
Brugada Syndrome Type 6 represents a specific genetic form of Brugada syndrome, a potentially life-threatening cardiac condition characterized by abnormal electrical activity in the heart. This inherited disorder primarily affects the heart’s sodium channels, leading to distinctive electrocardiogram (ECG) patterns and increased risk of sudden cardiac death, particularly during rest or sleep. The KCNE3 gene plays a crucial role in regulating cardiac ion channels, and mutations in this gene can disrupt normal heart rhythm regulation.
What Does the KCNE3 Gene Test Detect?
Our advanced Next-Generation Sequencing (NGS) technology provides comprehensive analysis of the KCNE3 gene to identify pathogenic variants associated with Brugada Syndrome Type 6. The test specifically examines:
- Complete coding regions of the KCNE3 gene
- Exon-intron boundaries for splice site mutations
- Known pathogenic variants linked to cardiac arrhythmias
- Novel genetic alterations affecting potassium channel function
- Inheritance patterns and familial risk assessment
Clinical Significance of KCNE3 Mutations
The KCNE3 gene encodes the MinK-related peptide 2 (MiRP2) protein, which forms part of the cardiac potassium channel complex. Mutations in this gene can alter the electrical properties of heart cells, leading to the characteristic ECG changes and arrhythmia susceptibility seen in Brugada Syndrome Type 6.
Who Should Consider KCNE3 Genetic Testing?
This specialized genetic test is recommended for individuals presenting with:
- Unexplained syncope or fainting episodes
- Family history of sudden cardiac death or Brugada syndrome
- Characteristic Brugada pattern on ECG (ST-segment elevation in right precordial leads)
- Documented ventricular arrhythmias without structural heart disease
- First-degree relatives of confirmed Brugada syndrome patients
- Individuals with nocturnal agonal respiration or seizure-like episodes
- Patients with fever-induced arrhythmic events
Symptoms and Clinical Presentation
Individuals with KCNE3-related Brugada Syndrome Type 6 may experience:
- Palpitations and irregular heartbeats
- Dizziness or lightheadedness
- Chest discomfort during rest
- Nocturnal seizures or abnormal breathing patterns
- Family history of early cardiac events
Benefits of KCNE3 Genetic DNA Testing
Undergoing KCNE3 genetic testing provides numerous clinical advantages:
- Accurate Diagnosis: Confirms or rules out genetic basis for cardiac symptoms
- Risk Stratification: Helps assess individual sudden cardiac death risk
- Family Screening: Enables targeted testing of at-risk relatives
- Treatment Guidance: Informs decisions about implantable cardioverter-defibrillator (ICD) placement
- Lifestyle Recommendations: Provides basis for activity restrictions and fever management
- Reproductive Planning: Offers information for family planning decisions
- Peace of Mind: Reduces uncertainty about cardiac symptoms
Understanding Your Test Results
Your KCNE3 genetic test results will fall into one of several categories:
Positive Result
A positive result indicates the presence of a pathogenic variant in the KCNE3 gene associated with Brugada Syndrome Type 6. This confirms the genetic diagnosis and enables:
- Implementation of appropriate cardiac monitoring
- Consideration of preventive therapies
- Family member screening recommendations
- Lifestyle modification guidance
Negative Result
A negative result suggests no pathogenic KCNE3 variants were detected. However, this does not completely rule out Brugada syndrome, as other genetic causes may be present. Further evaluation may be recommended.
Variant of Uncertain Significance (VUS)
Some genetic changes have unclear clinical significance. In these cases, ongoing research and family studies may help clarify the variant’s importance over time.
Test Details and Pricing
| Test Component | Details |
|---|---|
| Test Name | KCNE3 Gene Brugada Syndrome Type 6 NGS Genetic DNA Test |
| Regular Price | $700 USD |
| Discount Price | $500 USD |
| Turnaround Time | 3 to 4 Weeks |
| Sample Type | Blood, Extracted DNA, or One Drop Blood on FTA Card |
| Testing Method | Next-Generation Sequencing (NGS) Technology |
| Specialty | Cardiology and Genetics |
Pre-Test Requirements
Before undergoing KCNE3 genetic testing, we recommend:
- Comprehensive clinical history documentation
- Genetic counseling session with our certified genetic counselors
- Development of detailed family pedigree chart
- Review of current cardiac symptoms and ECG findings
- Discussion of potential implications for family members
Nationwide Testing Availability
We proudly offer KCNE3 genetic testing services across the United States with convenient locations in major metropolitan areas including New York, Los Angeles, Chicago, Houston, Phoenix, Philadelphia, San Antonio, San Diego, Dallas, and San Jose. Our state-of-the-art genetic testing facilities ensure consistent, high-quality results regardless of collection location.
Take Control of Your Cardiac Health Today
Don’t let uncertainty about cardiac symptoms or family history cause unnecessary worry. Our KCNE3 Gene Brugada Syndrome Type 6 NGS Genetic DNA Test provides the clarity needed for informed medical decisions and peace of mind. With our discounted price of $500 USD and comprehensive genetic analysis, you can take proactive steps toward understanding your cardiac health.
Ready to schedule your test? Contact our genetic specialists today at +1(267) 388-9828 or book your appointment online. Our team is available to answer your questions and guide you through the testing process with compassion and expertise.
